Business / Finance

RSS

Adeona reports $3,164,512 net revenue for 2010

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, reported its financial results for the year ended December 31, 2010, as well as updates since the beginning of the 4th quarter.

31 Mar 2011

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the fourth quarter and full-year ended December 31, 2010, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL and established 2011 financial guidance.

31 Mar 2011

Repro-Med Systems net revenue increases 30% for fiscal year ending February 28, 2011

Repro-Med Systems, Inc., dba RMS Medical Products, today announced unaudited financial results for its fiscal year ended February 28, 2011, showing increases in both domestic and international sales.

31 Mar 2011

Cellectis 2010 total operating revenues increase 55% to EUR 15.8M

Cellectis, the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.

31 Mar 2011

LecTec's cash and cash equivalent decreases to $8,689,280

LecTec Corporation announced today that it has released its fiscal 2010 financial information.

31 Mar 2011

AUXILIO reports $15.4 million net revenue for 2010

AUXILIO, Inc., the nation's pioneer and leading Managed Print Services (MPS) company for health care, announced its financial results for the 2010 fiscal year.

30 Mar 2011

Derma Sciences fourth quarter total sales increase 12% to record $15.3 million

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2010.

30 Mar 2011

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2010.

30 Mar 2011

Dr. Reddy’s acquires GSK's US penicillin facility and products

Dr. Reddy's Laboratories today announced the completion of the acquisition of GlaxoSmithKline's United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on Nov 23, 2010.

30 Mar 2011

TAP announces new corporate identity

The Automation Partnership, a leading supplier of innovative automation for life science applications today announced that the company will now be known as TAP Biosystems.

30 Mar 2011

Cephalon receives unsolicited proposal from Valeant

Cephalon, Inc. confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals International, Inc., on March 18th to acquire the Company for $73 per share and a second unsolicited proposal on March 25th to either acquire the Company for $73 per share or to purchase Cephalon's non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in the Company for $73 per share.

30 Mar 2011

SCOLR Pharma total revenue decreases 34% to $618,000 for 2010

SCOLR Pharma, Inc. today reported financial results for the twelve months ended December 31, 2010, and also provided updates on a number of key corporate objectives.

30 Mar 2011

CryoLife to acquire Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, and Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of patients with refractory angina resulting from diffuse coronary artery disease, today announced that the boards of directors of both companies have approved a definitive agreement under which CryoLife will acquire all of the outstanding shares of Cardiogenesis for $0.457 per share.

29 Mar 2011

Medwell announces service agreement with Spectral Diagnostics

Medwell Capital Corp. today announced that the service agreement under which Medwell provides clinical, regulatory and capital markets consulting services to Spectral Diagnostics has been increased to $1.5 million per year, from $1.0 million, effective January 2011, in exchange for an increased level of service.

29 Mar 2011

Elbit Imaging consolidated revenue is NIS 1,474 million for 2010

Elbit Imaging Ltd. announced today its results for the year 2010. Consolidated revenues in Year 2010 were NIS 1,474 million compared to NIS 698 million reported last year.

29 Mar 2011

Arena to sell 12,150,000 shares of its common stock

Arena Pharmaceuticals, Inc. announced today that it has agreed to sell 12,150,000 shares of its common stock, at a price of $1.46 per share, and 12,150 shares of its Series C Convertible Preferred Stock, at a price of $1,460 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization.

29 Mar 2011

Cephalon intends to make takeover bid for ChemGenex

Cephalon, Inc. and ChemGenex Pharmaceuticals Limited today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex.

29 Mar 2011

Lotus fiscal year revenue increases 28.7% to $72.7 million for 2010

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2010.

29 Mar 2011

EpiCept enters agreement with institutional investor to purchase 7.1 million shares of common stock

EpiCept Corporation announced today that it has entered into a definitive agreement with an institutional investor for the purchase of approximately 7.1 million shares of its common stock at $0.65 per share, and five and one half year warrants to purchase up to approximately 5.3 million shares of common stock at an exercise price of $0.72 per share that are not exercisable for six months following the closing date of the offering.

29 Mar 2011

GTCR completes Sterigenics acquisition

GTCR, a leading private equity firm, today announced it has successfully completed the acquisition of Sterigenics International, Inc., the leading global provider of contract sterilization and ionization services for medical devices, food products, and advanced applications, from Silverfleet Capital and PPM America Capital Partners.

28 Mar 2011